Lumendi, LLC, a U.S. subsidiary of Lumendi, Ltd. out of London, England, won FDA clearance for its DiLumen endolumenal therapy system. The system is designed to isolate a section of the large intestine, to position the endoscope within it for a good viewing angle, and to help with delivery of incision-free endolumenal therapies.
The DiLumen was an idea that came out of the Minimally Invasive New Technologies program (MINT) at Weill Cornell Medicine and New York-Presbyterian, and developed by MINT and Lumendi.
It consists of a sheath containing two inflatable balloons that’s placed over the colonoscope. Once inside, the balloons are inflated so that the tip of the colonoscope is positioned between the balloons. The volume between the balloons can now be treated while keeping the endoscope stable and near the center of the intestine.
“DiLumen’s use during flexible colonoscopy is an important technical advance in a field that has previously been defined by laparoscopic and open surgical procedures. DiLumen can stabilize a section of colon and facilitate the endoscopic removal of complex adenomas or polyps, with the potential to positively impact patient outcomes. Although reporting of results in patients awaits clinical studies, we are extremely optimistic that this technology will be transformative in treating digestive diseases,” said Jeffrey Milsom, M.D., co-inventor of DiLumen, Chief of Colorectal Surgery at New York-Presbyterian/Weill Cornell Medical Center and Co-Director of the MINT Program, and Professor of Surgery at Weill Cornell Medicine.
Link: Lumendi technology page…